Invesco Biotechnology & Genome ETF $PBE Shares Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lifted its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 9,169.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 342,971 shares of the company’s stock after purchasing an additional 339,271 shares during the period. Northwestern Mutual Wealth Management Co. owned about 10.68% of Invesco Biotechnology & Genome ETF worth $28,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Comerica Bank lifted its stake in shares of Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after purchasing an additional 175 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after purchasing an additional 245 shares during the period. NewEdge Advisors LLC increased its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after acquiring an additional 342 shares in the last quarter. Blair William & Co. IL increased its holdings in Invesco Biotechnology & Genome ETF by 150.0% in the 3rd quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock worth $70,000 after acquiring an additional 600 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter worth $82,000.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of NYSEARCA PBE opened at $80.39 on Tuesday. The firm has a market cap of $250.01 million, a PE ratio of 20.44 and a beta of 0.71. The firm has a fifty day moving average of $79.46 and a 200 day moving average of $80.49. Invesco Biotechnology & Genome ETF has a one year low of $60.87 and a one year high of $85.73.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.